PCE

A Nursing Perspective on PARP Inhibitors in Prostate Cancer

Episode Summary

The treatment landscape of metastatic castrate-resistant prostate cancer (mCRPC) is continually evolving. In this podcast, an advanced practice provider discusses recent evidence on PARP inhibitors for mCRPC and how they incorporate these data into clinical practice. Topics include the role of PARP inhibitors for mCRPC with mutations in homologous recombination repair genes, testing for BRCA1/2 and other homologous recombination repair mutations, approved indications for olaparib and rucaparib, managing adverse events with approved PARP inhibitors, and a look at the future of PARP inhibition in mCRPC.

Episode Notes

In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include:

• An overview of the PROpel study of olaparib and the TRITON study of rucaparib
• FDA-approved indications for olaparib and rucaparib
• Genetic and molecular testing for BRCA1/2 and other HRR mutations
• Managing adverse events associated with olaparib and rucaparib
• Monitoring for and managing anemia
• Gastrointestinal side effects
• Fatigue
• A look at the future of PARP inhibitors in mCRPC with combination approaches of AR-directed therapy and PARP inhibition

Presenter:
Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois

Link to full program:
PCE.is/Onc22